← All trials
NCT06126965
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 29, 2021
- Primary completion
- Jan 11, 2024
- Completion date
- May 31, 2024
- First posted
- Nov 13, 2023
- Last posted
- Nov 13, 2023
- Enrollment
- 740
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Kintor Pharmaceutical Inc,Lead sponsor
- Fudan UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Peking UniversityOfficial
- Government of ChinaCollaborator
- Fudan UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.